The prevalence of DM worldwide in 2021 was 6.1%, and continues to increase.16,17 The pharmacotherapy of DM includes hypoglycemics, such as insulins, sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, metformin, dipeptidyl peptidase-4 inhibitors, thiazolidinediones, and sulfonylureas. This evidence concerns the gene GLP1R and diabetes mellitus.